237 related articles for article (PubMed ID: 22639106)
41. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
42. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias.
Cheung MM; Chan JK; Wong KF
Semin Hematol; 2003 Jul; 40(3):221-32. PubMed ID: 12876671
[TBL] [Abstract][Full Text] [Related]
43. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology.
Jaffe ES; Chan JK; Su IJ; Frizzera G; Mori S; Feller AC; Ho FC
Am J Surg Pathol; 1996 Jan; 20(1):103-11. PubMed ID: 8540601
[TBL] [Abstract][Full Text] [Related]
44. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients.
Nagato T; Kobayashi H; Kishibe K; Takahara M; Ogino T; Ishii H; Oikawa K; Aoki N; Sato K; Kimura S; Shimizu N; Tateno M; Harabuchi Y
Clin Cancer Res; 2005 Dec; 11(23):8250-7. PubMed ID: 16322282
[TBL] [Abstract][Full Text] [Related]
45. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas.
Jung CK; Lee KY; Kim Y; Han K; Shim SI; Kim BK; Kang CS
Pathol Int; 2001 May; 51(5):355-63. PubMed ID: 11422793
[TBL] [Abstract][Full Text] [Related]
46. Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection.
Zhang Y; Ohyashiki JH; Takaku T; Shimizu N; Ohyashiki K
Br J Cancer; 2006 Feb; 94(4):599-608. PubMed ID: 16449999
[TBL] [Abstract][Full Text] [Related]
47. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.
Chan JK; Sin VC; Wong KF; Ng CS; Tsang WY; Chan CH; Cheung MM; Lau WH
Blood; 1997 Jun; 89(12):4501-13. PubMed ID: 9192774
[TBL] [Abstract][Full Text] [Related]
48. Involvement of the appendix in a relapsed case of primary nasal NK/T-cell lymphoma.
Tsujimura H; Takagi T; Tamaru J; Sakai C
Leuk Lymphoma; 2000 May; 37(5-6):633-4. PubMed ID: 11042526
[TBL] [Abstract][Full Text] [Related]
49. NK-cell lymphoma with nodal presentation and expression of cutaneous lymphocyte-associated antigen.
Chang ST; Liao YL; Lin SH; Chuang SS
Pathol Res Pract; 2010 Jul; 206(7):463-6. PubMed ID: 19628338
[TBL] [Abstract][Full Text] [Related]
50. L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma.
Obama K; Tara M; Niina K
Int J Hematol; 2003 Oct; 78(3):248-50. PubMed ID: 14604284
[TBL] [Abstract][Full Text] [Related]
51. Novel treatment for early-stage nasal natural killer/T-cell lymphoma: intra-maxillary arterial infusion chemotherapy with concomitant radiotherapy.
Takahara M; Nagato T; Kishibe K; Ueda S; Komabayashi Y; Yamashina M; Takahashi K; Harabuchi Y
Hematol Oncol; 2017 Jun; 35(2):158-162. PubMed ID: 26563973
[TBL] [Abstract][Full Text] [Related]
52. NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status.
Ko YH; Cho EY; Kim JE; Lee SS; Huh JR; Chang HK; Yang WI; Kim CW; Kim SW; Ree HJ
Histopathology; 2004 May; 44(5):480-9. PubMed ID: 15139996
[TBL] [Abstract][Full Text] [Related]
53. Aggressive natural killer cell leukemia or extranodal NK/T cell lymphoma? a case with nasal involvement.
Jin X; Xu Y; Zhang J; Li G; Huang D; Yang Y; He H
Diagn Pathol; 2017 Jun; 12(1):46. PubMed ID: 28623913
[TBL] [Abstract][Full Text] [Related]
54. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
[TBL] [Abstract][Full Text] [Related]
55. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions.
Zhang Y; Nagata H; Ikeuchi T; Mukai H; Oyoshi MK; Demachi A; Morio T; Wakiguchi H; Kimura N; Shimizu N; Yamamoto K
Br J Haematol; 2003 Jun; 121(5):805-14. PubMed ID: 12780797
[TBL] [Abstract][Full Text] [Related]
56. EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.
Takada H; Imadome KI; Shibayama H; Yoshimori M; Wang L; Saitoh Y; Uota S; Yamaoka S; Koyama T; Shimizu N; Yamamoto K; Fujiwara S; Miura O; Arai A
PLoS One; 2017; 12(3):e0174136. PubMed ID: 28346502
[TBL] [Abstract][Full Text] [Related]
57. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
Chiang AK; Tao Q; Srivastava G; Ho FC
Int J Cancer; 1996 Nov; 68(3):285-90. PubMed ID: 8903467
[TBL] [Abstract][Full Text] [Related]
58. Management of advanced NK/T-cell lymphoma.
Tse E; Kwong YL
Curr Hematol Malig Rep; 2014 Sep; 9(3):233-42. PubMed ID: 24924658
[TBL] [Abstract][Full Text] [Related]
59. Body cavity-based presentation of natural killer cell lymphoma.
Pullarkat VA; Medeiros LJ; Brynes RK
Leuk Lymphoma; 2005 Feb; 46(2):293-6. PubMed ID: 15621817
[TBL] [Abstract][Full Text] [Related]
60. [Extranodal NK/T-cell lymphoma].
Suzuki R
Nihon Rinsho; 2014 Mar; 72(3):524-30. PubMed ID: 24724414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
